Stoke Therapeutics, Inc. STOK SYNGAP1 — Operating Expenses
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingExpenses.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s syngap1 — operating expenses.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s SYNGAP1 — operating expenses?
- Stoke Therapeutics, Inc. (STOK) reported SYNGAP1 — operating expenses of -$745K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s SYNGAP1 — operating expenses changed year-over-year?
- Stoke Therapeutics, Inc.'s SYNGAP1 — operating expenses decreased by 117.8% year-over-year, from -$342K to -$745K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s SYNGAP1 — operating expenses?
- Over 2 years (2023 to 2025), Stoke Therapeutics, Inc.'s SYNGAP1 — operating expenses has grown at a 145.3% compound annual growth rate (CAGR), from -$554K to -$3.33M.
- What does SYNGAP1 — operating expenses mean?
- This metric represents the total costs directly attributable to the research, development, and clinical advancement of the SYNGAP1 therapeutic program. It captures the specific resource allocation required to move this pipeline candidate through its current stage of development, including preclinical studies and clinical trial activities. Monitoring these expenses provides insight into the company's capital commitment to this specific genetic disease program relative to its broader portfolio.